Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.

Alldredge B, Jordan A, Imitola J, Racke MK.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):56-59. doi: 10.1097/WNF.0000000000000268.

PMID:
29389745
2.

IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity.

Lee PW, Smith AJ, Yang Y, Selhorst AJ, Liu Y, Racke MK, Lovett-Racke AE.

JCI Insight. 2017 Sep 7;2(17). pii: 91663. doi: 10.1172/jci.insight.91663. [Epub ahead of print]

3.

Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation.

Racke MK, Imitola J.

JAMA Neurol. 2017 Apr 1;74(4):392-394. doi: 10.1001/jamaneurol.2016.5925. No abstract available.

PMID:
28241157
4.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

5.

Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7Rα.

Nuro-Gyina PK, Rieser EL, Granitto MC, Pei W, Liu Y, Lee PW, Aqel S, Zhang J, Lovett-Racke AE, Racke MK, Yang Y.

J Neuroinflammation. 2016 Dec 3;13(1):302.

6.

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.

Chen D, Ireland SJ, Remington G, Alvarez E, Racke MK, Greenberg B, Frohman EM, Monson NL.

J Immunol. 2016 Dec 1;197(11):4257-4265. Epub 2016 Oct 26.

7.

Care of persons with MS in clinical practice: Management by majority.

Marrie RA, Racke MK.

Neurol Clin Pract. 2016 Aug;6(4):288-290. doi: 10.1212/CPJ.0000000000000281. No abstract available.

8.

Therapeutic developments for autoimmune demyelinating diseases: Musings from an MD (mouse doctor).

Racke MK.

J Neuroimmunol. 2017 Mar 15;304:7-10. doi: 10.1016/j.jneuroim.2016.07.006. Epub 2016 Jul 20.

PMID:
27452124
9.

Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis.

Racke MK, Imitola J.

JAMA Neurol. 2016 Aug 1;73(8):910-2. doi: 10.1001/jamaneurol.2016.1535. No abstract available.

PMID:
27295341
10.

MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis.

Severin ME, Lee PW, Liu Y, Selhorst AJ, Gormley MG, Pei W, Yang Y, Guerau-de-Arellano M, Racke MK, Lovett-Racke AE.

Brain. 2016 Jun;139(Pt 6):1747-61. doi: 10.1093/brain/aww084. Epub 2016 Apr 28.

11.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
12.

Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.

Stüve O, Racke MK.

JAMA Neurol. 2016 May 1;73(5):496-7. doi: 10.1001/jamaneurol.2015.4841. No abstract available.

PMID:
26954286
13.

Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis.

Guerau-de-Arellano M, Liu Y, Meisen WH, Pitt D, Racke MK, Lovett-Racke AE.

J Autoimmune Disord. 2015;1(1). pii: 6.

14.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

PMID:
26621682
15.

Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.

Orack JC, Deleidi M, Pitt D, Mahajan K, Nicholas JA, Boster AL, Racke MK, Comabella M, Watanabe F, Imitola J.

Stem Cells Transl Med. 2015 Mar;4(3):252-60. doi: 10.5966/sctm.2014-0133. Epub 2015 Jan 15. Review.

16.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

17.

Is no evidence of disease activity a realistic goal for patients with multiple sclerosis?

Imitola J, Racke MK.

JAMA Neurol. 2015 Feb;72(2):145-7. doi: 10.1001/jamaneurol.2014.3860. No abstract available.

PMID:
25531742
18.

Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis.

Lee PW, Yang Y, Racke MK, Lovett-Racke AE.

Brain Behav Immun. 2015 May;46:44-9. doi: 10.1016/j.bbi.2014.12.007. Epub 2014 Dec 10.

19.

Impact of suppressing retinoic acid-related orphan receptor gamma t (ROR)γt in ameliorating central nervous system autoimmunity.

Yang Y, Winger RC, Lee PW, Nuro-Gyina PK, Minc A, Larson M, Liu Y, Pei W, Rieser E, Racke MK, Lovett-Racke AE.

Clin Exp Immunol. 2015 Jan;179(1):108-18. doi: 10.1111/cei.12441.

20.

Is T-bet a potential therapeutic target in multiple sclerosis?

Racke MK, Yang Y, Lovett-Racke AE.

J Interferon Cytokine Res. 2014 Aug;34(8):623-32. doi: 10.1089/jir.2014.0020. Review.

PMID:
25084179
21.

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK.

Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Review.

22.

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Nicholas JA, Racke MK, Imitola J, Boster AL.

Ther Adv Chronic Dis. 2014 Mar;5(2):62-8. doi: 10.1177/2040622313514790. Review.

23.

Multiple sclerosis: Five new things.

Nicholas JA, Boster AL, Racke MK.

Neurol Clin Pract. 2013 Oct;3(5):404-412. Erratum in: Neurol Clin Pract. 2014 Feb;4(1):4.

24.

Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.

Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E.

JAMA Neurol. 2013 Feb;70(2):248-51. No abstract available.

PMID:
23530268
25.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
26.
27.

miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.

Smith KM, Guerau-de-Arellano M, Costinean S, Williams JL, Bottoni A, Mavrikis Cox G, Satoskar AR, Croce CM, Racke MK, Lovett-Racke AE, Whitacre CC.

J Immunol. 2012 Aug 15;189(4):1567-76. doi: 10.4049/jimmunol.1103171. Epub 2012 Jul 6.

28.

Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling.

Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK.

J Biol Chem. 2012 Aug 10;287(33):28017-26. doi: 10.1074/jbc.M112.383380. Epub 2012 Jun 25.

29.

New technologies for biomarker discovery in multiple sclerosis.

Comabella M, Racke MK.

J Neuroimmunol. 2012 Jul 15;248(1-2):1. doi: 10.1016/j.jneuroim.2012.05.018. No abstract available.

PMID:
22726889
30.

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A.

J Cent Nerv Syst Dis. 2012 May 16;4:81-103. doi: 10.4137/JCNSD.S6692. Print 2012.

31.

Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity.

Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE.

Brain. 2011 Dec;134(Pt 12):3578-89. doi: 10.1093/brain/awr262. Epub 2011 Nov 15.

32.

miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing.

Guerau-de-Arellano M, Alder H, Ozer HG, Lovett-Racke A, Racke MK.

J Neuroimmunol. 2012 Jul 15;248(1-2):32-9. doi: 10.1016/j.jneuroim.2011.10.006. Epub 2011 Nov 9. Review.

33.

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.

Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M.

J Exp Med. 2011 Oct 24;208(11):2291-303. doi: 10.1084/jem.20100977. Epub 2011 Oct 10.

34.

What happens when natalizumab therapy is stopped?

Schaaf SM, Pitt D, Racke MK.

Expert Rev Neurother. 2011 Sep;11(9):1247-50. doi: 10.1586/ern.11.109.

PMID:
21864070
35.

TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE.

Huss DJ, Winger RC, Cox GM, Guerau-de-Arellano M, Yang Y, Racke MK, Lovett-Racke AE.

Eur J Immunol. 2011 Oct;41(10):2987-96. doi: 10.1002/eji.201141666. Epub 2011 Aug 30. Erratum in: Eur J Immunol. 2012 Nov;42(11):3084.

36.

Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis.

Smith AJ, Liu Y, Peng H, Beers R, Racke MK, Lovett-Racke AE.

J Neuroimmunol. 2011 Aug 15;237(1-2):33-8. doi: 10.1016/j.jneuroim.2011.05.012. Epub 2011 Jun 28.

37.

Because it is our journal.

Racke MK.

J Neuroimmunol. 2011 Apr;233(1-2):1-2. doi: 10.1016/j.jneuroim.2011.02.012. Epub 2011 Mar 22. No abstract available.

PMID:
21429595
38.

Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis.

Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ.

J Neuroimmunol. 2011 May;234(1-2):131-40. doi: 10.1016/j.jneuroim.2011.02.001. Epub 2011 Mar 11.

39.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stüve O, Shlomchik M, Eagar TN.

PLoS One. 2011 Feb 16;6(2):e17103. doi: 10.1371/journal.pone.0017103.

40.

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Racke MK, Lovett-Racke AE.

J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138. Review.

41.

Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs.

Yang Y, Lovett-Racke AE, Racke MK.

PPAR Res. 2010;2010:104705. doi: 10.1155/2010/104705. Epub 2010 Dec 22.

42.

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R.

Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354.

43.

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM.

Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851.

44.

Understanding the effects of FTY720 on leukocyte trafficking.

Racke MK.

Arch Neurol. 2010 Dec;67(12):1433-4. doi: 10.1001/archneurol.2010.299. No abstract available.

PMID:
21149807
45.

The potential role of B cell-targeted therapies in multiple sclerosis.

Boster A, Ankeny DP, Racke MK.

Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000. Review.

PMID:
21142258
46.

miRNAs in multiple sclerosis: regulating the regulators.

Guerau-de-Arellano M, Lovett-Racke AE, Racke MK.

J Neuroimmunol. 2010 Dec 15;229(1-2):3-4. doi: 10.1016/j.jneuroim.2010.08.025. No abstract available.

47.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL.

Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516.

48.

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O.

Arch Neurol. 2010 Aug;67(8):923-30. doi: 10.1001/archneurol.2010.161. Review.

49.

A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis.

Ligocki AJ, Lovato L, Xiang D, Guidry P, Scheuermann RH, Willis SN, Almendinger S, Racke MK, Frohman EM, Hafler DA, O'Connor KC, Monson NL.

J Neuroimmunol. 2010 Sep 14;226(1-2):192-3. doi: 10.1016/j.jneuroim.2010.06.016. Epub 2010 Jul 23.

50.

Translational research in neurology and neuroscience 2010: multiple sclerosis.

Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN.

Arch Neurol. 2010 Nov;67(11):1307-15. doi: 10.1001/archneurol.2010.158. Epub 2010 Jul 12. Review.

Supplemental Content

Loading ...
Support Center